Maxim raised the firm’s price target on Viking Therapeutics to $120 from $50 and keeps a Buy rating on the shares after the company announced that the Phase 2 VENTURE study of the company’s injectable GLP-1 drug, VK2735, met all the primary and secondary endpoints. Considering the data and market potential of GLP-1s, the firm is reducing its risk-adjustment for VK2735 and discount rating for Viking, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics Issues Regulation FD Disclosure Notice
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics rumor highlighted again by Betaville blog
- Viking Therapeutics price target raised to $35 from $30 at Stifel
- Viking Therapeutics price target raised to $38 from $32 at Truist
